{"id":50237,"date":"2022-10-28T19:02:28","date_gmt":"2022-10-28T17:02:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-sustained-release-excipients-market-trends-analysis-report-2022-a-2-4-billion-market-by-2030-opportunities-in-minimization-of-hepatic-first-pass-elimination-researchandmarkets-com\/"},"modified":"2022-10-28T19:02:28","modified_gmt":"2022-10-28T17:02:28","slug":"global-sustained-release-excipients-market-trends-analysis-report-2022-a-2-4-billion-market-by-2030-opportunities-in-minimization-of-hepatic-first-pass-elimination-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-sustained-release-excipients-market-trends-analysis-report-2022-a-2-4-billion-market-by-2030-opportunities-in-minimization-of-hepatic-first-pass-elimination-researchandmarkets-com\/","title":{"rendered":"Global Sustained Release Excipients Market Trends\/Analysis Report 2022: A $2.4 Billion Market by 2030 – Opportunities in Minimization of Hepatic First Pass Elimination – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Sustained Release Excipients Market Size, Share & Trends Analysis Report by Route Of Administration (Oral, Transdermal), by Technology (Transdermal, Implants), by Product (Gelatin, Sugars), and Segment Forecasts, 2022-2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global sustained release excipients market size is expected to reach USD 2.4 billion by 2030, registering a CAGR of 8.22%\n<\/p>\n

\nRise in the number of patent expirations, need for pediatric & geriatric dosage forms, and added benefits provided by sustained release formulations are factors that are positively contributing to the market potential.\n<\/p>\n

\nSustained release formulations significantly reduce dosage frequency and improve patient compliance. These factors are further aiding industry growth. In comparison to conventional drugs, sustained drug release technologies provide a wide range of benefits.\n<\/p>\n

\nReduced dosage frequency, improved patient compliance, maintenance of the constant level of drug in blood plasma, lower instances of toxicity due to overdose, and higher cost-effectiveness, in the long run, are some of the major advantages of using sustained release drug delivery systems.\n<\/p>\n

\nRegular consumption of oral conventional drugs generally results in undesired symptoms, such as gastrointestinal upset, cramps, nausea, and diarrhea. The use of sustained release drug formulations provides patients relief from these symptoms and helps maintain desired therapeutic drug levels in the body. Moreover, these have been increasing the adoption of sustained release formulations, enabling higher patient compliance and improved therapeutic effect.\n<\/p>\n

\nOver the past few years, there has been a global rise in antibiotic resistance. Overuse and misuse of conventional drug formulations have been identified as the major cause of antibiotic resistance. In some instances, patients recover within a few days of drug administration and discontinue the recommended dose of drugs, culminating in resistance.\n<\/p>\n

\nSuch resistance leads to higher medical costs, longer hospital stays, and a rise in mortality rate. The rise in the incidence of infectious and chronic diseases has also resulted in antibiotic resistance, which has negatively impacted the conventional dosage forms market. Thus, alternative procedures to treat and manage these diseases are being implemented.\n<\/p>\n

\nThe use of controlled release formulations has been extensively accepted among physicians to prevent antibiotic resistance. Since these formulations generate preferred therapeutic drug levels in blood plasma and decrease the dosage frequency, they are an ideal choice of formulations among physicians, which increases their demand in the industry.\n<\/p>\n

\nThe impact of disruptions on pharmaceutical production and subsequently on excipient demand affected by lockdowns and transport and travel bans across several countries due to the COVID-19 pandemic will be comparatively short-term. However, the supply disruptions due to extended lockdowns in different countries may have a more substantial impact on the oral solid dosage form drug manufacturing.\n<\/p>\n

\nThis, in turn, will significantly impact the excipients’ demand growth globally. There is a wide scope for growth of the industry in Europe, which includes France, Spain, and Italy. This is due to the rising adoption of advanced drugs in these countries. Moreover, regulatory authorities, such as the European Medicines Agency (EMA) and Medicines & Healthcare Products Regulatory Agency (MHRA), are constantly working toward ensuring high safety standards and easy access to low-cost drugs in this region.\n<\/p>\n

\nHigh disposable income, the presence of sophisticated healthcare infrastructure, and a rise in the number of product approvals are the factors expected to create growth opportunities in the Europe region.\n<\/p>\n

\nSustained release formulations are designed specifically in ways to reduce the dosage frequency. Thus, these formulations have high Active Pharmaceutical Ingredient (API) doses, which facilitate the maintenance of desired therapeutic levels. However, drug toxicity resulting from sustained release formulations is difficult to treat due to excess API.\n<\/p>\n

\nDrug retrieval in these cases becomes difficult as drugs are designed to deliver predetermined amounts at frequent time intervals. These are very rarely seen in sustained release formulations, which may hinder industry growth to a certain extent.\n<\/p>\n

\nSustained Release Excipients Market Report Highlights<\/strong>\n<\/p>\n